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Abstract
Acute renal failure refers to sudden deterioration in
biochemical and physiological functioning of kidneys and
often associated with multi organ failure. Continuous renal
replacement therapy (CRRT) holds special significance for
the treatment of renal failure due to a variety of factors. It is
believed that CRRT helps in restoration of acid-base
imbalances and electrolyte abnormalities. Along with that,
with gradual solute removal, it ensures haemodynamic
stability and prevents the risk of cerebral oedema in
neurosurgery patients. Besides this, several studies have
supported that CRRT enables practitioners to adjust drug
dosages and prevent drug accumulation and overdose. In
addition, gradual removal of solutes and metabolic waste
products helps to clear inflammatory mediators and ensure
adequate nutrition for patients and lead to improved renal
recovery. Therefore, this article will discuss the different
treatment modalities that encompass CRRT and explore the
indications and advantages of CRRT in acute renal failure.
Keywords: Acute renal failure, Continuous renal
replacement therapy.
Introduction
Continuous renal replacement therapy (CRRT) is
useful in the treatment of acute renal failure (ARF), in the
setting of hypotension associated with sepsis, liver disease or
cardiogenic shock. CRRT helps in volume management and
controls distinct acid-base and electrolyte abnormalities
through diffusion and convection.1 The requirement for
CRRT in different regions of the developed world are
reported to occur in 5-6% of critically ill patients.1 Hospital
mortality rate of patients with severe ARF has been reported
to be around 60%, and of those who survived to go home,
13% were dependent on some form of maintenance renal
replacement therapy.2
The term CRRT refers to a technique which allows
water and solutes to move across a semi- permeable
membrane to support or take over the function of the kidney
in the purification of blood and in the maintainance of water
and electrolyte balance.3 Diffusion, convection and
adsorption are the three mechanisms used for solute removal
during CRRT. Diffusion is based on the principle that
molecules and ions flow randomly from an area of higher
concentration of solute across a membrane to an area of lower
concentration to establish an equilibrium. The speed of
diffusion is related to the concentration gradient. Convection
is the movement of solutes through a membrane by the force
of water. Very large molecules are able to move through, if
the flow of water through membrane is fast enough. Process
of convection is maximized by using replacement fluid.4
Adsorption is the removal of solutes from the blood because
they cling to the membrane. It basically refers to the binding
of molecules to any surface. Ultra filtration refers to the
passage of water through a membrane under a pressure
gradient. The rate of ultra filtration depends upon the pressure
applied to the filter and on the rate at which the blood passes
through the filter. Several treatment modalities can be offered
while patients are on continuous renal replacement therapy.
Slow Continuous Ultra filtration (SCUF):
The circuit for SCUF is quite simple. Blood enters the
extracorporeal circuit through an access line, passes through
the haemofilter, and returns to the patient's circulation via the
return line. As the blood passes through the filter, ultra
filtration takes place and effluent collects in the effluent bag.
Effluent is any fluid that exits the haemofilter and is delivered
Vol. 62, No. 3, March 2012 276
Continuous renal replacement therapy
Gulzar Salman Amlani
Aga Khan University, School of Nursing, Karachi.
Special Communication
Figure-1: Circuit for slow continuous ultra filtration (SCUF).
to a waste bag. Pumps control blood flow and fluid removal
rates. This process is followed by the principle of ultra
filtration. No dialysate or replacement fluids are used.
However, significant amounts of fluid are removed from the
patient. This therapy is quite appropriate for severely
hypervolaemic patients. Clinically, practitioners use this
therapy to remove fluid from the patient over a short (8-12
hour) time period and then the treatment can be switched to
another appropriate therapy.
Continuous Veno Venous Haemofiltration
(CVVH):
Continuous veno-venous haemofiltration (CVVH)
involves convection and ultra filtration mechanisms. Blood
enters the extracorporeal circuit through an access line and
passes through the haemofilter. The replacement fluids can be
delivered either pre or post filter. Solute removal is
accomplished by convection and the blood then returns to the
patient circulation via the return line. The effluent bag not
only contains Ultra filtrate from the patient, but also the
replacement fluid volume. 
CVVH aims for maximizing convective removal of
small and middle molecules. Replacement solutions are
used to drive this convective transportation. The standard
fluid usage is 25 ml/kg/hr so in average size patient total
fluid used is 60-72 litres in 24 hour period to achieve the
desired clearance of solutes. Because of its simplicity and
efficiency in taking over for the failing kidney, continuous
veno venous haemofiltration (CVVH) is widely used to
manage acute renal failure.5 Pre or Post dilution fluid
replacement has its own implications. Pre dilution
replacement fluid lowers haematocirt levels thus decreases
the risk of clotting and ensures higher Ultra filtration.
However, the effluent chemistries do not reflect true plasma
solute losses. On the other hand, with post dilutional
replacement fluids, there may be a need to increase
anticoagulation to prevent filter clotting. A benefit that post-
dilution replacement fluid offers is that the effluent
characteristics truly indicate the plasma solute losses.
Continuous Veno Venous Haemodialysis
(CVVHD)
Continuous veno venous haemodialysis (CVVHD)
works on the principle of dialysis and ultra filtration. Blood
enters the extracorporeal circuit through an access line,
passes through the haemofilter; the dialysate is added on the
fluid side of the filter to increase solute exchange by
diffusion. The blood then returns to the patient circulation
by the return line. The effluent bag not only contains ultra
filtrate from the patient, but also the dialysate. Since
replacement fluid is not administered with this therapy. ultra
filtration rates are lower than with CVVH therapy. Unlike
intermittent haemodialysis, it is the dialysate flow rate
rather than the blood flow rate that will determine
clearances.
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Figure-2: Circuit for continuous veno venous Haemofiltration (CVVH). Figure-3: Circuit for continuous veno venous Haemodialysis (CVVHD).
Continuous Veno Venous Haemodiafiltration
(CVVHDF):
Continuous veno venous haemodiafiltration
(CVVHDF) works on the principle of dialysis and
convection. Blood enters the extracorporeal circuit through
an access line, passes through the haemofilter; the dialysate
and replacement fluids are added on the fluid side of the filter
to increase solute exchange by diffusion and convection. The
blood then returns to the patient's circulation by the return
line. The effluent bag not only contains ultra filtrate from the
patient, but also the dialysate and the replacement fluid.
CVVHDF is the therapy that merges the mechanisms of
CVVH and CVVHD using both the principles of convection
and diffusion. Dialysate functions to remove small molecular
weight substances and replacement fluid allow additional
convective clearance of middle size molecules. In this
therapy, diffusion provides excellent electrolyte and
metabolite control, and middle molecules such as TNF, IL-1,
cytokines, and mediators of septic shock are cleared by
convective transport mechanisms. 
In CVVH solutes are removed only by convection,
and solute removal is limited by the ultra filtration rate. By
adding dialysis to filtration, as in CVVHDF, solutes are
removed by both convection and diffusion, increasing the
removal of small molecules more than middle-sized and large
molecules.4,6
Several factors can be considered for selecting the
criteria for the initiation of renal replacement therapy as
anuria or oliguria (urine output, 200 ml/12 hours),
hyperkalaemia (K . 6.5 mmol/l), severe acidaemia (pH .
7.1), azotaemia (BUN < 20mg/dl).7 Other criteria for the
initiation of replacement therapy could be clinically
significant organ oedema (particularly lung), uraemic
encephalopathy, uraemic pericarditis, uraemic
neuropathy/myopathy, hyperthermia or drug overdose with
a dialyzable product.3,7 There is no consensus in the medical
community on when to start CRRT. The decision to start
CRRT depends on individual patient's condition.
CRRT requires the placement and maintenance of a
vascular access. Most often a double lumen vascath is
inserted to aid in the process. Internal jugular and femoral
veins are different sites that can be used. Subclavian site is
usually avoided due to high risk of subclavian vein stenosis.
However, the selection for appropriate site depends on the
patient's condition. For example a femoral catheter could not
be a very good choice for a patient with ascites due to
increased intra abdominal pressure.
CRRT proves to be effective in acute renal failure as
it helps to maintain electrolyte and acid base balance. It
corrects renal acidosis by clearing acids and other metabolic
waste products. Along with that, it ensures adequate nutrition
and clears inflammatory mediators. CRRT offers better
control of metabolic acidosis and serum electrolyte levels
compared to IHD. However, due to the high phosphate
clearance and the simultaneous initiation of nutritional
support, hypophosphataemia may develop during CRRT and
thus should be monitored and treated.1 Another study
supports that acid base imbalance can be corrected and
sustained more effectively using CRRT due to the continuous
supply of buffer contained within the dialysate and/or
replacement fluid.8 CRRT also removes excess fluid volume.
Fluid overload is controlled more effectively using CRRT
especially in the setting of haemodynamically unstable
patient. The advantage of CRRT is that the composition of
replacement fluid and dialysate can be modified easily and
lower rate of blood flow promotes cardiovascular stability.
The use of CRRT is now an established primary treatment
modality for renal replacement as conventional IHD
increases the frequency of hypotensive episodes in
haemodynamically unstable patients.7 Besides this, a slower
blood flow speed than conventional IHD allow the rate of
fluid removal during CRRT to be achieved over a longer
period of time and along with the use of biocompatible
membranes, reduce the incidence of haemodynamic
instability. In addition, the CRRT therapy ensures adequate
mean arterial pressure (MAP) and prevents cardiovascular
complications. Along with that, CRRT has positive effects in
patients who are at risk of increased intracranial pressure such
as neurosurgical patients, patients with encephalitis or
meningo-encephalitis or hepatic encephalopathy. Since, the
solutes are removed slowly and gradually during CRRT,
therefore, it prevents the risk of cerebral oedema. In addition,
CRRT has been demonstrated to prevent the surges in
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Figure-4: Circuit for continuous veno venous Haemodiafiltration (CVVHDF).
intracranial pressure associated with intermittent therapies
that can perpetuate further injury.1 As many antibiotics are
excreted through the kidneys, the antibiotic doses may have
to be reduced or discontinued because of nephrotoxicity. The
critically ill patient with renal failure is at risk for drug
accumulation and overdose, but also for under dosing, that
may be life-threatening.4 However, physicians can plan
effective antibiotic regimen when patients are started on
continuous renal replacement therapy. Therefore, the
principles of drug removal during CRRT need to be clearly
understood.4 Therefore, deliberate attention is required from
the physician and pharmacologist while prescribing and
adjusting drugs appropriately.
CRRT can lead to some complications. Anticoagulation
in CRRT can lead to cause systemic bleeding episodes. Vigilant
care is directed to look for the signs and symptoms of occult or
fresh bleeding.9,10 Moreover, the patient's haemoglobin levels
are checked as per the institutional policy and patient's
condition. Besides this, the dialysate and replacement fluids are
kept at room temperature and administration of large volumes
of room temperature fluids can cause hypothermia. Fluids
containing bicarbonate cannot be warmed as warming can
convert bicarbonate into carbon dioxide bubbles. Therefore,
general warming interventions are required. On the other hand,
patients may get infection because of this invasive procedure.
So, nursing care is focused on maintaining asepsis. Another
complication that may occur during CRRT is the development
of emboli.10 Specific attention is paid while priming and CRRT
circuit is routinely checked for the presence of air to prevent air
embolus.
Continuous Renal Replacement Therapy
(CRRT) versus Intermittent Haemodialysis
(IHD); Comparison and Contrast:
Intermittent haemodailysis (IHD) is commonly used
for the treatment of renal failure. High blood flow rate (200-
500 ml/minute) and high dialysate flow rate (500-800
ml/minute) can be used in order to achieve high solute
clearances over a short period of time.11 On the other hand,
CRRT is most frequently used in patients who are
haemodynamically unstable and can not tolerate IHD, usually
because of sepsis or cardiac problem. It is rightly believed
that CRRT is associated with a significantly higher mean
arterial pressure (MAP). Along with this, the need to escalate
inotropic or pressor support is decreased while patients are on
CRRT as compared to IHD.12 However; patients on CRRT
modality are prone to continuous anticoagulation and
hypothermia that might adversely affect the outcome. Several
clinical trials support that CRRT is associated with a
significantly increased risk of recurrent filter clotting and
bleeding tendencies as compared to IHD.13 Besides this, IHD
is cost effective and cheaper as compared to CRRT. The
training expenditure and resource management in terms of
equipment are low with IHD. On the other hand, CRRT
requires a specialized equipment and training of staff,
additional supplies (especially replacement fluids), and
consumes greater health care resources than IHD. A recently
published randomized trial of intermittent haemodialysis
versus CRRT demonstrated that even the sickest of patients
could be safely treated with intermittent haemodialysis given
the significantly higher cost of CRRT.14 Pannu, etal
performed a systemic review of 30 randomized control trials
and 8 prospective cohort studies in 2008 and concluded that
there is no difference in survival between CRRT and IHD,
and there was no evidence that either CRRT or IHD was
superior for reducing mortality. Although cohort data
suggests a lower risk of hypotension among CRRT
recipients.14 Despite apparent advantages over intermittent
therapies in unstable patients, superiority of CRRT with
respect to mortality or recovery of renal function has not been
demonstrated.12 The research findings also reflect that the
creatinine clearance and blood urea nitrogen levels also do
not differ significantly when compared in both the therapies.
As the solute clearance depends on the dialysis prescription
and the operational characteristics; it is also possible to
increase clearances in CRRT by adjustment of the ultra
filtration rate and dialysate flow rate. In contrast, if IHD
techniques are operational at maximum capability, it is
difficult to enhance clearances except by increasing the size
of the membrane or the duration of therapy. In general, IHD
techniques are limited by available time, and in catabolic
patients it may not be possible to achieve a desired level of
solute control even by maximizing the operational
characteristics.15
This still remains a controversial issue. The decision
to use CRRT or IHD in patients with ARF is mainly based
on the physician preference at the particular point in time
and patient's assessment findings such as electrolyte and
acid-base status, uraemia, nutritional requirements, urine
output, haemodynamic status, and the clinical condition of
each individual patient. A practical approach could be to
consider both, IHD and CRRT as complementary therapies
that can be interchangeably utilized in ARF patients
according to individual patient's needs. It is anticipated that
a multidisciplinary approach will bring more advancement
in this complex field.
A large randomized controlled trial and further meta
analysis is recommended to explore further advantages and
disadvantages and practical implications of various treatment
modalities of CRRT and IHD. More extensive research is
required to identify which therapy is more appropriate and
applicable based on different patient's co morbid and patient's
diseases process. 
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